Absci Names Gerry Muhle Chief Commercial Officer
The Vancouver, Wash.-based biotech company added a commercial leader with more than 25 years of pharmaceutical and aesthetics experience.
Updated on Nov. 12, 2026 in People

Absci Corporation appointed Gerry Muhle as Chief Commercial Officer. Muhle has more than 25 years of commercial leadership experience across prescription medicines, aesthetics and consumer skincare.
Why it matters
The appointment brings commercial expertise to Absci as it advances ABS-201, its AI-developed candidate for pattern hair loss and endometriosis. The company's Vancouver, Wash. headquarters anchors its research and development operations.
Muhle brings more than 25 years of commercial leadership, with prior roles at Galderma, Allergan/AbbVie and GSK. The filing does not disclose his compensation or the scope of his commercial mandate at Absci.
The players
Absci Corporation
Absci is a Vancouver, Wash.-based biotechnology company that combines AI models with a synthetic biology data engine to develop drug candidates.
Gerry Muhle
Muhle is a pharmaceutical and aesthetics executive with more than 25 years of commercial leadership experience across prescription medicines and consumer skincare.
The details
Muhle previously served as Senior Vice President and Head of Global Product Strategy at Galderma, where he drove growth for Dysport, Sculptra and Cetaphil. He also led international strategic marketing for an aesthetics portfolio including Botox and Juvéderm at Allergan/AbbVie, and served as Vice President and Head of the Neurosciences Centre of Excellence at GSK.
Timeline
November 12, 2026: Absci announces Muhle's appointment as Chief Commercial Officer.
Q4 2026: Interim proof-of-concept data for ABS-201 is expected.
December 2026: Absci anticipates reporting 13-week interim proof-of-concept data.
Early 2027: Full proof-of-concept data for ABS-201 is expected.
2027: A planned Phase 2 endometriosis trial of ABS-201 is set to begin.
Market Landscape
Absci's Integrated Drug Creation platform pairs AI models with wet-lab validation in a continuous feedback loop. The commercial hire signals the company is preparing for market positioning as ABS-201 advances toward interim data in late 2026.
For investors tracking Absci, the hire signals a push toward commercial readiness as ABS-201 moves through its proof-of-concept timeline. Patients with pattern hair loss or endometriosis will not see any change in access until the drug completes clinical development.
The takeaway
Watch the December 2026 interim data for ABS-201, since that readout will show whether the company's commercial build-out is matched by clinical progress.
What happens next
Absci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026, with full proof-of-concept data expected in early 2027.
Further reading
Explore more business people coverage for executive moves shaping the biotech sector.
Source note: This article includes information reported by The Manila times.










